Update from Aclaris Therapeutics Inc. (ACRS): A steady trajectory

Aclaris Therapeutics Inc. (NASDAQ: ACRS) closed the day trading at $8.14 down -1.45% from the previous closing price of $8.26. In other words, the price has decreased by -$0.12 from its previous closing price. On the day, 1004652 shares were traded. ACRS stock price reached its highest trading level at $8.62 during the session, while it also had its lowest trading level at $8.04.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".



For a better understanding of ACRS, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.60 and its Current Ratio is at 10.60. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stifel on December 14, 2022, initiated with a Buy rating and assigned the stock a target price of $29.

On December 01, 2022, Goldman started tracking the stock assigning a Buy rating and target price of $25.

On October 06, 2022, BTIG Research started tracking the stock assigning a Buy rating and target price of $32.BTIG Research initiated its Buy rating on October 06, 2022, with a $32 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 09 when Manion Douglas J. bought 6,500 shares for $7.74 per share. The transaction valued at 50,278 led to the insider holds 6,500 shares of the business.

Walker Neal sold 30,240 shares of ACRS for $382,070 on Mar 03. The Director now owns 1,273,202 shares after completing the transaction at $12.63 per share. On Mar 03, another insider, Monahan Joseph, who serves as the Chief Scientific Officer of the company, sold 16,037 shares for $12.63 each. As a result, the insider received 202,615 and left with 147,724 shares of the company.

Valuation Measures:

For the stock, the TTM Price-to-Sale (P/S) ratio is 17.69 while its Price-to-Book (P/B) ratio in mrq is 2.75.

Stock Price History:

Over the past 52 weeks, ACRS has reached a high of $18.96, while it has fallen to a 52-week low of $5.77. The 50-Day Moving Average of the stock is 13.95, while the 200-Day Moving Average is calculated to be 15.25.

Shares Statistics:

Over the past 3-months, ACRS traded about 992.54K shares per day on average, while over the past 10 days, ACRS traded about 2.85M shares per day. A total of 66.70M shares are outstanding, with a floating share count of 60.26M. Insiders hold about 0.20% of the company’s shares, while institutions hold 96.50% stake in the company. Shares short for ACRS as of Jan 30, 2023 were 2.65M with a Short Ratio of 3.30M, compared to 2.99M on Dec 29, 2022. Therefore, it implies a Short% of Shares Outstanding of 3.97% and a Short% of Float of 4.12%.

Earnings Estimates

Current recommendations for the stock of the company come from 9 analysts. On average, analysts expect EPS of -$0.45 for the current quarter, with a high estimate of -$0.36 and a low estimate of -$0.49, while EPS last year was -$0.37. The consensus estimate for the next quarter is -$0.43, with high estimates of -$0.35 and low estimates of -$0.48.

Analysts are recommending an EPS of between -$1.25 and -$1.5 for the fiscal current year, implying an average EPS of -$1.37. EPS for the following year is -$1.69, with 9 analysts recommending between -$1.51 and -$2.04.

Revenue Estimates

9 analysts predict $1.99M in revenue for the current quarter. It ranges from a high estimate of $6.2M to a low estimate of $1.12M. As of the current estimate, Aclaris Therapeutics Inc.’s year-ago sales were $1.5M, an estimated increase of 32.60% from the year-ago figure. For the next quarter, 4 analysts are estimating revenue of $1.52M, an increase of 4.60% less than the figure of $32.60% in the same quarter last year. There is a high estimate of $1.9M for the next quarter, whereas the lowest estimate is $1.12M.

A total of 9 analysts have provided revenue estimates for ACRS’s current fiscal year. The highest revenue estimate was $28.2M, while the lowest revenue estimate was $23.12M, resulting in an average revenue estimate of $23.99M. In the same quarter a year ago, actual revenue was $6.76M, up 254.80% from the average estimate. Based on 9 analysts’ estimates, the company’s revenue will be $6.65M in the next fiscal year. The high estimate is $10.6M and the low estimate is $4.48M. The average revenue growth estimate for next year is down -72.30% from the average revenue estimate for this year.